BeEAM conditioning regimen is a safe, efficacious and economical alternative to BEAM chemotherapy

Abstract In many stem cell transplant centres, BCNU, etoposide, cytarabine and melphalan (BEAM) high-dose chemotherapy (HDCT) has been replaced by the more economic and available bendamustine, etoposide, cytarabine, melphalan (BeEAM) regimen. However, there is a paucity of information on the efficac...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Logan Hahn, Hyun Lim, Tanner Dusyk, Waleed Sabry, Mohamed Elemary, Julie Stakiw, Pat Danyluk, Mark Bosch
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/23828b0a1c934656bc12d62a0f32093a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:23828b0a1c934656bc12d62a0f32093a
record_format	dspace
spelling	oai:doaj.org-article:23828b0a1c934656bc12d62a0f32093a2021-12-02T16:15:06ZBeEAM conditioning regimen is a safe, efficacious and economical alternative to BEAM chemotherapy10.1038/s41598-021-93516-x2045-2322https://doaj.org/article/23828b0a1c934656bc12d62a0f32093a2021-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-93516-xhttps://doaj.org/toc/2045-2322Abstract In many stem cell transplant centres, BCNU, etoposide, cytarabine and melphalan (BEAM) high-dose chemotherapy (HDCT) has been replaced by the more economic and available bendamustine, etoposide, cytarabine, melphalan (BeEAM) regimen. However, there is a paucity of information on the efficacy and safety of BeEAM HDCT. We describe our experience with BeEAM HDCT in terms of safety, efficacy and cost-savings. We compare overall and progression-free survival to a cohort of patients previously transplanted at our institution with the older BEAM regimen. We performed a retrospective chart review of 41 lymphoma patients undergoing BeEAM HDCT at the Royal University Hospital in Saskatoon, Saskatchewan between 2015 and 2019 to elicit regimen safety in the first 100 days post-transplant. Furthermore, we calculated overall and progression-free survival and constructed corresponding Kaplan–Meier curves, comparing the results to a historical cohort of BEAM patients (n = 86). Finally, we conducted an economic analysis using the financials available at our centre’s pharmacy. With regards to BeEAM HDCT, we report a 100-day transplant-related mortality of 2.4%. Additionally, we report acceptable rates of typhlitis (27%), grade III–IV mucositis (4.9%) and grade III–IV nephrotoxicity (2.4%). In terms of overall and progression-free survival, we found no statistical difference between BeEAM and BEAM (p = 0.296; 0.762, respectively). Finally, our economic analysis revealed a net savings of $21,200 CAD per transplant when BeEAM is used in replacement of BEAM. The acceptable safety profile of BeEAM and its comparable efficacy to BEAM are encouraging for the perseverance of this cost-effective HDCT regimen.Logan HahnHyun LimTanner DusykWaleed SabryMohamed ElemaryJulie StakiwPat DanylukMark BoschNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Logan Hahn Hyun Lim Tanner Dusyk Waleed Sabry Mohamed Elemary Julie Stakiw Pat Danyluk Mark Bosch BeEAM conditioning regimen is a safe, efficacious and economical alternative to BEAM chemotherapy
description	Abstract In many stem cell transplant centres, BCNU, etoposide, cytarabine and melphalan (BEAM) high-dose chemotherapy (HDCT) has been replaced by the more economic and available bendamustine, etoposide, cytarabine, melphalan (BeEAM) regimen. However, there is a paucity of information on the efficacy and safety of BeEAM HDCT. We describe our experience with BeEAM HDCT in terms of safety, efficacy and cost-savings. We compare overall and progression-free survival to a cohort of patients previously transplanted at our institution with the older BEAM regimen. We performed a retrospective chart review of 41 lymphoma patients undergoing BeEAM HDCT at the Royal University Hospital in Saskatoon, Saskatchewan between 2015 and 2019 to elicit regimen safety in the first 100 days post-transplant. Furthermore, we calculated overall and progression-free survival and constructed corresponding Kaplan–Meier curves, comparing the results to a historical cohort of BEAM patients (n = 86). Finally, we conducted an economic analysis using the financials available at our centre’s pharmacy. With regards to BeEAM HDCT, we report a 100-day transplant-related mortality of 2.4%. Additionally, we report acceptable rates of typhlitis (27%), grade III–IV mucositis (4.9%) and grade III–IV nephrotoxicity (2.4%). In terms of overall and progression-free survival, we found no statistical difference between BeEAM and BEAM (p = 0.296; 0.762, respectively). Finally, our economic analysis revealed a net savings of $21,200 CAD per transplant when BeEAM is used in replacement of BEAM. The acceptable safety profile of BeEAM and its comparable efficacy to BEAM are encouraging for the perseverance of this cost-effective HDCT regimen.
format	article
author	Logan Hahn Hyun Lim Tanner Dusyk Waleed Sabry Mohamed Elemary Julie Stakiw Pat Danyluk Mark Bosch
author_facet	Logan Hahn Hyun Lim Tanner Dusyk Waleed Sabry Mohamed Elemary Julie Stakiw Pat Danyluk Mark Bosch
author_sort	Logan Hahn
title	BeEAM conditioning regimen is a safe, efficacious and economical alternative to BEAM chemotherapy
title_short	BeEAM conditioning regimen is a safe, efficacious and economical alternative to BEAM chemotherapy
title_full	BeEAM conditioning regimen is a safe, efficacious and economical alternative to BEAM chemotherapy
title_fullStr	BeEAM conditioning regimen is a safe, efficacious and economical alternative to BEAM chemotherapy
title_full_unstemmed	BeEAM conditioning regimen is a safe, efficacious and economical alternative to BEAM chemotherapy
title_sort	beeam conditioning regimen is a safe, efficacious and economical alternative to beam chemotherapy
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/23828b0a1c934656bc12d62a0f32093a
work_keys_str_mv	AT loganhahn beeamconditioningregimenisasafeefficaciousandeconomicalalternativetobeamchemotherapy AT hyunlim beeamconditioningregimenisasafeefficaciousandeconomicalalternativetobeamchemotherapy AT tannerdusyk beeamconditioningregimenisasafeefficaciousandeconomicalalternativetobeamchemotherapy AT waleedsabry beeamconditioningregimenisasafeefficaciousandeconomicalalternativetobeamchemotherapy AT mohamedelemary beeamconditioningregimenisasafeefficaciousandeconomicalalternativetobeamchemotherapy AT juliestakiw beeamconditioningregimenisasafeefficaciousandeconomicalalternativetobeamchemotherapy AT patdanyluk beeamconditioningregimenisasafeefficaciousandeconomicalalternativetobeamchemotherapy AT markbosch beeamconditioningregimenisasafeefficaciousandeconomicalalternativetobeamchemotherapy
_version_	1718384280016519168

BeEAM conditioning regimen is a safe, efficacious and economical alternative to BEAM chemotherapy

Ejemplares similares